Can Amitriptyline Cause Cardiac Arrhythmia?
Yes, amitriptyline definitively causes cardiac arrhythmias and carries significant proarrhythmic risk, including QT prolongation, torsade de pointes, AV block, and increased risk of cardiac arrest and sudden cardiac death.
Mechanisms of Arrhythmia
Amitriptyline induces arrhythmias through multiple cardiac mechanisms:
- Cardiac sodium channel blockade: Prolongs the cardiac action potential and refractory period, delays AV conduction, and causes rate-dependent QRS prolongation 1, 2
- QT interval prolongation: Inhibits delayed rectifier potassium currents (both IKr and IKs), with documented IC50 values of 2.5 μM for Kv7.1/KCNE1 channels 3
- Ryanodine receptor activation: Causes spontaneous calcium release from the sarcoplasmic reticulum, a mechanism directly linked to ventricular arrhythmias 4
- AV node conduction delay: Results in AV block 5
Clinical Evidence of Arrhythmia Risk
The European Heart Journal guideline 5 specifically identifies amitriptyline as having documented cases of torsade de pointes (TdP), classifying it among tricyclic antidepressants that:
- Prolong the QT interval
- Have few but documented reports of TdP, especially related to amitriptyline treatment
- Increase cardiac arrest risk with an odds ratio of 1.69 in registry studies (mean patient age 67 years)
The FDA label 6 explicitly contraindicates amitriptyline with cisapride "due to the potential for increased QT interval and increased risk for arrhythmia" and warns that tricyclic antidepressants "particularly when given in high doses, have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time" 6.
Specific Arrhythmias Documented
- Torsade de pointes (though incidence not well established)
- Ventricular tachycardia
- Wide QRS and sinusoidal ventricular tachycardia (sodium channel blocker toxicity)
- Ventricular premature beats (isolated, couplets, triplets)
- Severe ventricular repolarization disturbances
At therapeutic doses 5:
- Sinus tachycardia (most common, due to anticholinergic effects)
- AV block
- Increased sudden cardiac death risk
Rate-Dependent Effects
Critical finding: Arrhythmia risk is strongly heart rate-dependent 8. In experimental studies, amitriptyline induced ventricular tachycardia in:
- 0% of dogs with fixed pacing at 100 bpm
- 100% of dogs during accelerated pacing
- 83% of dogs with unimpeded sinus tachycardia (mean HR 185 bpm vs 115 bpm in those without VT, p=0.0015)
This explains why sympathetic activation and tachycardia substantially increase arrhythmia risk.
High-Risk Populations
Elderly patients are at particularly elevated risk 5:
- Mean age in cardiac arrest studies: 67-74 years
- Often have serious somatic comorbidity
- More sensitive to anticholinergic effects including tachycardia
Patients with pre-existing cardiac conditions face compounded risk:
- Ischemic heart disease
- Heart failure
- Congenital long QT syndrome
- Previous myocardial infarction (contraindicated in acute recovery phase 6)
Clinical Management Implications
Before initiating amitriptyline:
- Obtain baseline ECG to assess QTc interval, conduction abnormalities, and signs of heart disease 5
- Screen for cardiac risk factors: chest pain, dyspnea, palpitations, syncope, family history of sudden cardiac death
- Review all medications for QT-prolonging drugs or CYP2D6 inhibitors
During treatment:
- Monitor for sinus tachycardia (increases arrhythmia substrate)
- Consider ECG monitoring in elderly patients, those with cardiac disease, or when using higher doses
- Avoid concomitant QT-prolonging medications 6
- Magnesium supplementation may attenuate effects by reducing ryanodine receptor open probability 4
Common pitfall: The FDA label 6 warns that tricyclic antidepressants produce arrhythmias "particularly when given in high doses," but registry data 5 show increased cardiac arrest risk even at therapeutic doses (OR 1.69), meaning standard dosing still carries measurable risk.
Contraindication: Do not use with cisapride or during acute MI recovery phase 6.